Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS)
CNY39.00
+3.55 (+10.01%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
Building1,Ningbo R&D Park 315040
Ningbo, CN
Ningbo, CN
CEO
Cheng Zhi Yao
Website
menovopharm.com
IPO
2017-04-10
ISIN CNE100002Y25
Description
Ningbo Menovo Pharmaceutical Co., Ltd. operates across the full spectrum of pharmaceutical activities, encompassing the research, development, production, and distribution of medicinal products. Their extensive product line features Active Pharmaceutical Ingredients (APIs), intermediate chemicals, and finished drug formulations. These offerings are designed to address a wide range of therapeutic areas, including cardiovascular, central nervous system, respiratory, oncological, anti-infective, digestive, and geriatric disorders, as well as antiviral treatments. The company commenced operations in 2004 and maintains its principal place of business in Ningbo, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY39.00
+3.55 (+10.01%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
42M
Beta
-0.10
Float Shares
238.04M
Free Float %
99.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.92% | -8.34% | -27.83% | +101.43% | +123.83% | +134.30% | +200.53% | +122.07% | +61.75% | +274.11% | +274.11% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
39.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.15
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+9.5% ★ Q1'26: +22.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+51.6% ★ Q1'26: +30.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-3.7% Q1'26: -15.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+11.4% Q1'26: +14.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+4.8% Q1'26: +5.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.9% Q1'26: +13.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.52× Q1'26: 6.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
605.32M
est: 686.00M (-11.8%)
|
848.96M
est: 780.00M (+8.8%)
|
1.18B
est: 1.19B (-0.6%)
|
1.19B
est: 1.47B (-18.7%)
|
1.26B
est: 1.26B (-0.2%)
|
1.46B
est: 1.69B (-14.0%)
|
1.22B
est: 1.50B (-18.6%)
|
1.37B
est: 1.48B (-7.3%)
|
1.50B
est: 1.66B (-9.3%)
|
1.97B
1.97B – 1.97B
+19.1% YoY
|
2.32B
2.32B – 2.32B
+17.4% YoY
|
| EBITDA |
101.17M
est: 161.20M (-37.2%)
|
176.23M
est: 183.28M (-3.8%)
|
275.58M
est: 278.93M (-1.2%)
|
318.66M
est: 344.88M (-7.6%)
|
306.89M
est: 296.31M (+3.6%)
|
510.54M
est: 398.28M (+28.2%)
|
151.55M
est: 351.29M (-56.9%)
|
265.65M
est: 330.86M (-19.7%)
|
307.19M
est: 370.10M (-17.0%)
|
440.91M
440.91M – 440.91M
+19.1% YoY
|
517.74M
517.74M – 517.74M
+17.4% YoY
|
| EBIT |
68.76M
est: 101.77M (-32.4%)
|
126.38M
est: 115.72M (+9.2%)
|
211.90M
est: 176.11M (+20.3%)
|
231.11M
est: 217.74M (+6.1%)
|
207.95M
est: 187.08M (+11.2%)
|
412.22M
est: 251.46M (+63.9%)
|
37.94M
est: 221.80M (-82.9%)
|
136.10M
est: 205.22M (-33.7%)
|
171.61M
est: 229.56M (-25.2%)
|
273.48M
273.48M – 273.48M
+19.1% YoY
|
321.13M
321.13M – 321.13M
+17.4% YoY
|
| Net Income |
44.68M
est: 128.29M (-65.2%)
|
96.35M
est: 143.53M (-32.9%)
|
150.90M
est: 147.85M (+2.1%)
|
155.96M
est: 202.73M (-23.1%)
|
142.53M
est: 164.62M (-13.4%)
|
338.86M
est: 281.08M (+20.6%)
|
11.59M
est: 119.25M (-90.3%)
|
66.81M
est: 93.53M (-28.6%)
|
102.23M
est: 128.33M (-20.3%)
|
160.96M
160.96M – 160.96M
+25.4% YoY
|
210.98M
210.98M – 210.98M
+31.1% YoY
|
| SGA |
95.74M
est: 48.00M (+99.5%)
|
128.28M
est: 54.58M (+135.0%)
|
184.27M
est: 83.06M (+121.9%)
|
169.96M
est: 102.69M (+65.5%)
|
193.53M
est: 88.23M (+119.3%)
|
248.85M
est: 118.60M (+109.8%)
|
213.97M
est: 104.60M (+104.6%)
|
218.15M
est: 215.11M (+1.4%)
|
100.19M
est: 240.62M (-58.4%)
|
286.65M
286.65M – 286.65M
+19.1% YoY
|
336.61M
336.61M – 336.61M
+17.4% YoY
|
| EPS |
0.24
est: 0.60 (-60.2%)
|
0.48
est: 0.67 (-28.8%)
|
0.75
est: 0.69 (+8.0%)
|
0.76
est: 0.95 (-20.2%)
|
0.68
est: 0.77 (-12.0%)
|
1.61
est: 1.32 (+22.0%)
|
0.05
est: 0.56 (-91.1%)
|
0.31
est: 0.43 (-27.9%)
|
0.48
est: 0.59 (-18.6%)
|
0.74
0.74 – 0.74
+25.4% YoY
|
0.97
0.97 – 0.97
+31.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
71.60M
OE per share TTM
0.25
Owner's Yield
0.71%
Maintenance CapEx ratio
153.49%
Maint CapEx / Avg PPE
121.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 129.8K | 0.29% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 79.0K | 0.39% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
72.9K
Shares Outstanding
238.37M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Cheng Zhi Yao | GM & Chairman | — | male |
| Gaofeng Ying | Chief Financial Officer, Board Secretary, Accounting Supervisor & Director | — | male |
| Jian Xu | Deputy General Manager | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603538.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
